Back to top
more

Arena Pharmaceuticals, Inc. (ARNA)

(Delayed Data from NSDQ)

$47.60 USD

47.60
308,048

+1.62 (3.52%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.68 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue?

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Arena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% Higher

    by Zacks Equity Research

    Arena Pharmaceuticals (ARNA) was a big mover last session, as the company saw its shares rise nearly 11% on the day.

      Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene

      by Zacks Equity Research

      The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.

        Company News For Mar 21, 2018

        by Zacks Equity Research

        Companies in the news are: ARNA,MULE,CRM,PLCE,HQY

          Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal

          by Zacks Equity Research

          Arena's (ARNA) ulcerative colitis candidate, etrasimod leads to clinical remission in 33% of the patients.

            Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y

            by Zacks Equity Research

            Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.

              Options Traders Expect Huge Moves in Arena Pharmaceuticals (ARNA) Stock

              by Zacks Equity Research

              Surging implied volatility makes Arena Pharmaceuticals (ARNA) stock lucrative to the option traders.

                Arena (ARNA) Posts Narrower-Than-Expected Q4 Loss, Shares Up

                by Zacks Equity Research

                Arena (ARNA) posted narrower-than-expected loss in the fourth quarter of 2017. However, revenues decreased significantly year over year.

                  Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code

                  by Zacks Equity Research

                  Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.

                    What's in the Cards for Arena (ARNA) This Earnings Season?

                    by Zacks Equity Research

                    Although Arena's (ARNA) only approved product, Belviq, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q4.

                      Orexigen Struggles as Contrave Commercialization Costs Rise

                      by Zacks Equity Research

                      Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

                        Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

                        by Zacks Equity Research

                        Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.

                          Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat

                          by Zacks Equity Research

                          Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.

                            What's in the Cards for Arena (ARNA) This Earnings Season?

                            by Zacks Equity Research

                            Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.

                              Orexigen's (OREX) Contrave Sales Improving on Promotions

                              by Zacks Equity Research

                              Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

                                J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use

                                by Zacks Equity Research

                                Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.

                                  Arena Pharmaceuticals (ARNA) Down 1.5% Since Earnings Report: Can It Rebound?

                                  by Zacks Equity Research

                                  Arena Pharmaceuticals (ARNA) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected

                                    by Zacks Equity Research

                                    Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.

                                      Will Expenses Hit Envision Healthcare (EVHC) Q2 Earnings?

                                      by Zacks Equity Research

                                      Envision Healthcare's (EVHC) second-quarter earnings may suffer from high operating cost and low revenues from the ambulatory service unit.

                                        What's in the Cards for Kite Pharma (KITE) in Q2 Earnings

                                        by Zacks Equity Research

                                        With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.

                                          Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?

                                          by Zacks Equity Research

                                          Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.

                                            Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses

                                            by Zacks Equity Research

                                            Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.

                                              Sucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y

                                              by Zacks Equity Research

                                              Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in Japan, which drove the company's top line. The company is also working on expanding its pipeline and Amitizia's label.

                                                BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

                                                by Zacks Equity Research

                                                BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.

                                                  Can Myriad Genetics (MYGN) Spring a Surprise in Q4 Earnings?

                                                  by Zacks Equity Research

                                                  Myriad Genetics (MYGN) is well poised to deliver favorable results in Q4 riding on a diversified portfolio with products like Vectra DA test.